Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir.
Luppi
M
M
Trovato
R
R
Barozzi
P
P
Vallisa
D
D
Rossi
G
G
Re
A
A
Ravazzini
L
L
Potenza
L
L
Riva
G
G
Morselli
M
M
Longo
G
G
Cavanna
L
L
Roncaglia
R
R
Torelli
G
G
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019288:Herpesvirus 8, Human / Q000187:drug effects*; D006801:Humans; D015552:Injections, Intralesional; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000821:virology; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D012074:Remission Induction; D013997:Time Factors
D000970:Antineoplastic Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir